Maiwei Biology (688062.SH): Application for market approval of 9MW0813 injection has been accepted.

Medview Bio (688062.SH) announced that the company recently received an "Acceptance Notice" issued by the National Medical Products Administration for the approval of the marketing license application for 9MW0813 injection. It is intended for the treatment of diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (nAMD). It is reported that 9MW0813 injection is a biosimilar of aflibercept (Eylea), a fusion protein formed by the extracellular binding domain of VEGFR-1 and VEGFR-2 with the Fc segment of human immunoglobulin, capable of binding to VEGF-A and PlGF.